R-Bridge Financing: A Major Step for Cancer Diagnostics
R-Bridge has made waves in the healthcare sector by offering bespoke financing of US$40 million structured as a synthetic royalty. This unique financial arrangement is designed to support the innovative efforts of Mirxes, a company specializing in early detection solutions for cancer through cutting-edge miRNA technology.
Mirxes: Pioneering Cancer Early Detection
Mirxes, a forward-thinking miRNA tech company, focuses on developing non-invasive blood tests that aid in the early detection of various cancers. Their flagship product, GASTROClear, is the first regulatory-approved In Vitro Diagnostic (IVD) test for gastric cancer screening worldwide. With impressive sensitivity rates, GASTROClear is changing the landscape of cancer diagnostics since it gained approval in Singapore.
Innovations in Medical Technology
Mirxes is committed to expanding its offerings by exploring diagnostic solutions for other cancer types such as lung, liver, and colorectal cancer. Their extensive patent portfolio, with over 90 patents, reflects their dedication to revolutionizing how cancer is detected and treated.
Impacts of R-Bridge’s Investment
The recent synthetic royalty-backed financing from R-Bridge is tailored for Mirxes, providing a flexible repayment structure aimed at aligning with their immediate strategic goals. This funding will significantly bolster Mirxes' efforts to commercialize their innovative technologies in new and expanding markets.
Commitment to Healthcare Advancements
Dr. Michael Keyoung, Senior Managing Director at CBC Group, highlights the importance of early cancer detection, particularly as Asia grapples with an aging population and an increase in cancer incidence. By supporting Mirxes through strategic financing, R-Bridge facilitates the growth of their transformative technological platform, aimed at making cancer detection globally accessible.
Strengthening Healthcare Solutions
Dr. Zhou Lihan, Co-Founder and CEO of Mirxes, echoes this sentiment by expressing pride in partnering with R-Bridge to advance their mission of deploying innovative cancer screening tests that save lives. This collaboration is critical for accelerating Mirxes' expansion in the burgeoning Asia-Pacific markets.
About CBC Group and R-Bridge
R-Bridge Healthcare Fund is an affiliate of CBC Group, Asia's largest healthcare-dedicated asset management firm, overseeing over US$9 billion in assets. Established to offer non-dilutive financing options for healthcare companies, R-Bridge focuses on facilitating growth through financing solutions that leverage royalties and other cash flows derived from healthcare products and services.
Investing in Health Innovation
Founded in 2020, R-Bridge continues to raise investment funds aimed at enhancing healthcare delivery. Their commitment reflects a broader goal to generate attractive returns for investors while supporting essential innovations within the healthcare sector.
Mirxes: Leading the Charge in RNA Technology
Since its inception in 2014, Mirxes has pioneered the development of innovative cancer detection tests utilizing their proprietary RNA technology platform. By collaborating with leading academic clinical institutions, Mirxes is building a strong portfolio of diagnostic tests for several high-incidence cancers.
Frequently Asked Questions
What is the significance of R-Bridge's US$40M financing?
This financing will enable Mirxes to expand its innovative approaches to cancer early detection and commercialize their technologies in new markets.
How does GASTROClear work?
GASTROClear is a blood-based test that provides accurate screening for gastric cancer, demonstrating high sensitivity rates for early-stage cancers.
What types of cancer is Mirxes developing tests for?
Mirxes is focused on developing tests for lung, liver, colorectal, and gastric cancers, among others.
Who leads R-Bridge's initiatives?
Dr. Michael Keyoung serves as the Senior Managing Director and leads the healthcare financing efforts at CBC Group.
What future plans does Mirxes have?
Mirxes aims to continue expanding its diagnostic solutions and refine its clinical pipeline, improving cancer detection methods globally.
